Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-12-07
DOI
10.3389/fphar.2018.01443
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells
- (2018) Qi Lai et al. ONCOGENE
- Abstract CT059: Epigenetic tumor remodelling to improve the efficacy of immune checkpoint blockade: the NIBIT-M4 clinical trial
- (2018) Anna M. Di Giacomo et al. CANCER RESEARCH
- Epigenetics and immunotherapy: The current state of play
- (2017) Jennifer Dunn et al. MOLECULAR IMMUNOLOGY
- Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
- (2016) S. Vasu et al. BLOOD
- Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
- (2016) Simone Jueliger et al. Epigenetics
- IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression
- (2016) Xiaoran Zhang et al. NEURO-ONCOLOGY
- Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy
- (2015) M. Maio et al. CLINICAL CANCER RESEARCH
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
- (2015) Jean-Pierre J Issa et al. LANCET ONCOLOGY
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Epigenetics Meets Immune Checkpoints
- (2015) Alessia Covre et al. SEMINARS IN ONCOLOGY
- Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models
- (2015) A Covre et al. OncoImmunology
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts
- (2014) Pragya Srivastava et al. LEUKEMIA RESEARCH
- Epigenetic drugs as immunomodulators for combination therapies in solid tumors
- (2014) Luca Sigalotti et al. PHARMACOLOGY & THERAPEUTICS
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
- (2010) Paul W. Hollenbach et al. PLoS One
- Azacitidine for the treatment of myelodysplastic syndrome
- (2009) Vince D Cataldo et al. Expert Review of Anticancer Therapy
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now